DEA Releases List of Nearly 7,000 Medical Marijuana Business Applications Under Trump’s Rescheduling Order

Nearly 7,000 medical marijuana business applications appear to be represented on a newly released Drug Enforcement Administration (DEA) list identifying applicants seeking federal registration under President Donald Trump’s partial marijuana rescheduling order.

The DEA’s applicant list is intended to provide a public accounting of state-licensed medical marijuana operators that submitted applications within the federal government’s initial registration window. The records distinguish applicants by state and business activity, including dispensaries, manufacturers and distributors.

Oklahoma accounted for the most applications by a wide margin, with over 2,400, including 940 dispensaries, 345 distributors and 1,161 manufacturers. Florida ranked second with over 800 applications, followed by California with 770, Maine with 320 and Pennsylvania with 230. Nationwide, the list includes 4,120 dispensary applications, 2,080 manufacturer applications and 710 distributor applications, for a total of nearly 7,000.

The applications stem from an April 28 federal rule that moved marijuana products covered by qualifying state medical marijuana licenses, along with FDA-approved marijuana products, from Schedule I to Schedule III of the Controlled Substances Act.

That order established a new registration process allowing state-licensed medical marijuana businesses to seek federal authorization to manufacture, distribute or dispense marijuana for medical purposes.

Under the rule, businesses that submitted applications within 60 days of its publication were given expedited consideration. Those applicants are allowed to continue operating in accordance with their state-issued medical marijuana licenses while their federal applications remain pending.

The initial application window closed June 26, although DEA has continued accepting applications from medical marijuana businesses seeking registration.

The federal rule also directs DEA to make every effort to process applications submitted during the initial 60-day period within six months of publication. That six-month period ended October 28, although the requirement does not guarantee that every application will be approved within that timeframe.

Importantly, the new list should not be interpreted as showing that nearly 7,000 businesses have received federal registrations. Applications remain subject to DEA review, and a single company may operate multiple licensed facilities or seek authorization for more than one business activity.

Federal regulations require DEA to evaluate applications under public-interest standards and applicable international treaty requirements. Registrations may be denied when those standards are not satisfied, and federal authorization remains tied to the underlying state medical marijuana license.

The registration process is separate from the broader federal marijuana rescheduling proceedings, which concern whether marijuana generally should be moved from Schedule I to Schedule III. While the April order established Schedule III status for qualifying medical marijuana products, marijuana intended for recreational use remains in Schedule I.

The release of the applicant information provides a new opportunity to examine participation in the federal registration process, including how applications are distributed geographically and across different sectors of the medical marijuana industry.